Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
B4GALT7
Introduction
Beta-1,4-galactosyltransferase 7 also known as galactosyltransferase I is an enzyme that in humans is encoded by the B4GALT7 gene.[1][1][2][2][3] Galactosyltransferase I catalyzes the synthesis of the glycosaminoglycan-protein linkage in proteoglycans.[4] Proteoglycans in turn are structural components of the extracellular matrix that is found between cells in connective tissues.
Function
Function
Galactosyltransferase I is one of seven β-1,4-galactosyltransferase (β4GalT) enzymes. These enzymes are type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose; all transfer galactose in a β-1,4 linkage to similar acceptor sugars: GlcNAc, Glc, and Xyl. Each beta4GalT has a distinct function in the biosynthesis of different glycoconjugates and saccharide structures. As type II membrane proteins, they have an N-terminal hydrophobic signal sequence that directs the protein to the Golgi apparatus and which then remains uncleaved to function as a transmembrane anchor. By sequence similarity, the beta4GalTs form four groups: β4GalT1 and β4GalT2, β4GalT3 and β4GalT4, β4GalT5 and β4GalT6, and β4GalT7. The enzyme encoded by this gene attaches the first galactose in the common carbohydrate-protein (GlcA-β-1,3-Gal-β-1,3-Gal-β-1,4-Xyl-beta1-O-Ser) linkage found in proteoglycans. Manganese is required as a cofactor. This enzyme differs from the other six beta4GalTs because it lacks the conserved β4GalT1-β4GalT6 Cys residues and it is located in cis-Golgi instead of trans-Golgi.[3]
Clinical significance
Clinical significance
Mutations in the B4GALT7 gene that result in a defective galactosyltransferase I enzyme with reduced or absent activity are associated with progeroid type Ehlers-Danlos syndrome.[2][4][5][6] Since mutations in B4GALT7 impair a glycosylation pathway, the resulting subtype of Ehlers-Danlos syndrome may be considered a congenital disorder of glycosylation (CDG), according to the new CDG nomenclature.
Mutations in B4GALT7 cause Larsen syndrome .Cartault, F; Munier, P; Jacquemont, M. L.; Vellayoudom, J; Doray, B; Payet, C; Randrianaivo, H; Laville, J. M.; Munnich, A; Cormier-Daire, V (2014). “Expanding the clinical spectrum of B4GALT7 deficiency: Homozygous p.R270C mutation with founder effect causes Larsen of Reunion Island syndrome”. European Journal of Human Genetics. 23: 49–53. doi:10.1038/ejhg.2014.60. PMC 4266744. PMID 24755949.
References
References
- ↑ 1.0 1.1 Okajima T, Yoshida K, Kondo T, Furukawa K (Sep 1999). “Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans”. J Biol Chem. 274 (33): 22915–8. doi:10.1074/jbc.274.33.22915. PMID 10438455.
- ↑ 2.0 2.1 2.2 Almeida R, Levery SB, Mandel U, Kresse H, Schwientek T, Bennett EP, Clausen H (Oct 1999). “Cloning and expression of a proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I. A seventh member of the human beta4-galactosyltransferase gene family”. J Biol Chem. 274 (37): 26165–71. doi:10.1074/jbc.274.37.26165. PMID 10473568.
- ↑ 3.0 3.1 “Entrez Gene: B4GALT7 xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I)”.
- ↑ 4.0 4.1 Okajima T, Fukumoto S, Furukawa K, Urano T (October 1999). “Molecular basis for the progeroid variant of Ehlers-Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I gene”. J. Biol. Chem. 274 (41): 28841–4. doi:10.1074/jbc.274.41.28841. PMID 10506123.
- ↑ Quentin E, Gladen A, Rodén L, Kresse H (Aug 1990). “A genetic defect in the biosynthesis of dermatan sulfate proteoglycan: galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome”. Proceedings of the National Academy of Sciences of the United States of America. 87 (4): 1342–6. doi:10.1073/pnas.87.4.1342. PMC 53471. PMID 2106134.
- ↑ Furukawa K, Okajima T (December 2002). “Galactosyltransferase I is a gene responsible for progeroid variant of Ehlers-Danlos syndrome: molecular cloning and identification of mutations”. Biochim. Biophys. Acta. 1573 (3): 377–81. doi:10.1016/S0304-4165(02)00406-3. PMID 12417421.
External links
External links
- Human B4GALT7 genome location and B4GALT7 gene details page in the UCSC Genome Browser.
Further reading
Further reading
- Amado M, Almeida R, Schwientek T, Clausen H (2000). “Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions”. Biochim. Biophys. Acta. 1473 (1): 35–53. doi:10.1016/S0304-4165(99)00168-3. PMID 10580128.
- Seidler DG, Faiyaz-Ul-Haque M, Hansen U, et al. (2007). “Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlers-Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I (beta4GalT-7)”. J. Mol. Med. 84 (7): 583–94. doi:10.1007/s00109-006-0046-4. PMID 16583246.
- Gulberti S, Lattard V, Fondeur M, et al. (2005). “Phosphorylation and sulfation of oligosaccharide substrates critically influence the activity of human beta1,4-galactosyltransferase 7 (GalT-I) and beta1,3-glucuronosyltransferase I (GlcAT-I) involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans”. J. Biol. Chem. 280 (2): 1417–25. doi:10.1074/jbc.M411552200. PMID 15522873.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). “Complete sequencing and characterization of 21,243 full-length human cDNAs”. Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Clark HF, Gurney AL, Abaya E, et al. (2003). “The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment”. Genome Res. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMC 403697. PMID 12975309.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proceedings of the National Academy of Sciences of the United States of America. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Kuroiwa A, Matsuda Y, Okajima T, Furukawa K (2000). “Assignment of human xylosylprotein beta-1,4-galactosyltransferase gene (B4GALT7) to human chromosome 5q35.2→q35.3 by in situ hybridization”. Cytogenet. Cell Genet. 89 (1–2): 8–9. doi:10.1159/000015578. PMID 10894925.
- Kresse H, Rosthøj S, Quentin E, et al. (1987). “Glycosaminoglycan-free small proteoglycan core protein is secreted by fibroblasts from a patient with a syndrome resembling progeroid”. American Journal of Human Genetics. 41 (3): 436–53. PMC 1684193. PMID 3631078.